<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924337</url>
  </required_header>
  <id_info>
    <org_study_id>PXL008-016</org_study_id>
    <secondary_id>2016-001821-14</secondary_id>
    <nct_id>NCT02924337</nct_id>
  </id_info>
  <brief_title>Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Placebo and Active Controlled Crossover Study to Assess the Effect of Single Dose Administration of 2 Doses of Imeglimin on QT/QTc Intervals in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of a single therapeutic dose and a single
      supra-therapeutic dose of imeglimin on the QT/QTc interval
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTcF (deltaQTcF)</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Qt Interval, Variation in</condition>
  <arm_group>
    <arm_group_label>Imeglimin therapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imeglimin supratherapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet, oral, single dose (400 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imeglimin</intervention_name>
    <arm_group_label>Imeglimin therapeutic dose</arm_group_label>
    <arm_group_label>Imeglimin supratherapeutic dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  BMI between 18.5 and 29.9 kg/m2

          -  weighing between 55 and 95 kg

          -  willing to use reliable contraception

          -  able to give fully informed written consent.

        Exclusion Criteria:

          -  Pregnant or lactating woman, or sexually active woman of child-bearing potential not
             using highly effective contraception

          -  clinically relevant abnormal medical history, surgery or concurrent medical condition;
             acute or chronic illness

          -  clinically significant QT/QTc interval prolongation at Baseline

          -  history of drug-induced or risk factors for Torsade de Pointes

          -  any contraindication to moxifloxacin

          -  severe adverse reaction to any drug or sensitivity to the trial medication or its
             components

          -  significant food allergy; use of vitamins, herbal medicines, prescription or
             over-the-counter medication (with the exception of paracetamol [acetaminophen] and
             oral contraceptives for women) within 20 days or 6 half-lives before first dose of
             trial medication

          -  participation in other clinical trials of unlicensed or prescription medicines, or
             loss of more than 400 mL blood, within the 3 months before first dose of trial
             medication

          -  drug or alcohol abuse; smoking of more than 5 cigarettes, 1 cigars or 1 pipes daily

          -  regular consumption of more than 5 cups of caffeinated drinks per day

          -  positive test for hepatitis A, B &amp; C, HIV

          -  objection by a General Practitioner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Dubourg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Poxel SA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascale Fouqueray, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Poxel SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QT/QTC interval</keyword>
  <keyword>Hypoglycemic Agents</keyword>
  <keyword>Imeglimin</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

